Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Autore:
Noseworthy, JH; OBrien, PC; Petterson, TM; Weis, J; Stevens, L; Peterson, WK; Sneve, D; Cross, SA; Leavitt, JA; Auger, RG; Weinshenker, BG; Dodick, DW; Wingerchuk, DM; Rodriguez, M;
Indirizzi:
Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 urol, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn Rochester MN USA 55905 stat, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn, Dept Ophthalmol, Rochester, MN 55905 USA Mayo Clin &Mayo Fdn Rochester MN USA 55905 lmol, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn, Dept Neurol, Scottsdale, AZ USA Mayo Clin & Mayo Fdn Scottsdale AZ USA , Dept Neurol, Scottsdale, AZ USA
Titolo Testata:
NEUROLOGY
fascicolo: 11, volume: 56, anno: 2001,
pagine: 1514 - 1522
SICI:
0028-3878(20010612)56:11<1514:ARTOII>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
CENTRAL-NERVOUS-SYSTEM; PLACEBO-CONTROLLED TRIAL; REMITTING MULTIPLE-SCLEROSIS; PROMOTES CNS REMYELINATION; GUILLAIN-BARRE-SYNDROME; PLASMA-EXCHANGE; MYASTHENIA-GRAVIS; DOUBLE-BLIND; NEUROMUSCULAR DISORDERS; IMMUNE GLOBULIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Noseworthy, JH Mayo Clin & Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA Mayo Clin & Mayo Fdn 200 1st St SW Rochester MN USA 55905 A
Citazione:
J.H. Noseworthy et al., "A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis", NEUROLOGY, 56(11), 2001, pp. 1514-1522

Abstract

Objective: To determine whether TV immunoglobulin (Mg) reverses chronic visual impairment in MS patients with optic neuritis (ON). Methods: In this double-blind, placebo-controlled Phase Il trial, 55 patients with persistentacuity loss after ON were randomized to receive either Mg 0.4 g/kg daily for 5 days followed by three single infusions monthly for 3 months, or placebo. Results: The trial was terminated by the National Eye Institute becauseof negative results when 55 of the planned 60 patients had been enrolled. Fifty-two patients completed the scheduled infusions, and 58 patients completed 12 months of follow-up. Analysis of this data indicated that a difference between treatment groups was not observed for the primary outcome measure, improvement in logMAR visual scores at 6 months (p = 0.766). Exploratory secondary analyses suggested that Mg treatment was associated with improvement in visual function (including logMAR visual scores at 6 months and visual fields at 6 and 12 months) in patients with clinically stable MS during the trial. Conclusions: Mg administration does not reverse persistent visual loss from ON to a degree that merits general use.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:15:05